Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 5/20 | 0.53 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.53 |
| ▸ | USP1 | O94782 | 12/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | IL6 | P05231 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20157460 | 0.90 | NUDT1 (0.42) | TLR7NUDT1USP1 | |
| SCHEMBL20157629 | 0.89 | TLR7 (0.50) | TLR7NUDT1USP1ADORA3 | |
| SCHEMBL21759581 | 0.88 | TLR7 (0.55) | TLR7NUDT1USP1ADORA3IL6 | |
| SCHEMBL20157800 | 0.88 | ADORA3 (0.58) | TLR7NUDT1USP1ADORA3 | |
| SCHEMBL20157644 | 0.87 | USP1 (0.45) | TLR7NUDT1USP1ADORA3 | |
| SCHEMBL20157617 | 0.86 | TLR7 (0.51) | TLR7NUDT1USP1ADORA3IL6 | |
| SCHEMBL20157626 | 0.85 | TLR7 (0.53) | TLR7NUDT1USP1ADORA3 | |
| SCHEMBL21351784 | 0.84 | TLR7 (0.52) | TLR7NUDT1USP1ADORA3IL6 | |
| SCHEMBL20157575 | 0.84 | TLR7 (0.52) | TLR7NUDT1USP1ADORA3IL6 | |
| SCHEMBL20157676 | 0.84 | USP1 (0.53) | TLR7NUDT1USP1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11084818-B2 | Nitrogen-containing heterocyclic compound, preparation method, intermediate, pharmaceutical composition and use | HEPO PHARMACEUTICAL CO., LTD. (CN) | 2021-08-10 | — | — | US | disclosed |
| US-20200062758-A1 | Nitrogen-Containing Heterocyclic Compound, Preparation Method, Intermediate, Pharmaceutical Composition and use | HEPO PHARMACEUTICAL CO., LTD. (CN) | 2020-02-27 | — | — | US | disclosed |
| EP-3539963-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE | Livo (Shanghai) Pharmaceutical Co., Ltd (CN) | 2019-09-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11084818-B2 | Nitrogen-containing heterocyclic compound, preparation method, intermediate, pharmaceutical composition and use | TLR7, TLR9, TLR4 | TLR7 1/4885NUDT1 15/4885USP1 3017/4885 |
| US-20200062758-A1 | Nitrogen-Containing Heterocyclic Compound, Preparation Method, Intermediate, Pharmaceutical Composition and use | TLR7, TLR9, NOD1 | TLR7 1/4885NUDT1 19/4885USP1 2778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.